SciELO - Scientific Electronic Library Online

 
vol.31 número2Urología antigua en el Reino de Valencia: OrígenesTendencias divergentes en la mortalidad por cáncer de próstata en la Comunidad Autónoma de Andalucía (1975-2004) índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Actas Urológicas Españolas

versão impressa ISSN 0210-4806

Resumo

STEVEN, A.  e  KAPLAN, M.D.. The role of Muscarinic Receptor Antagonists in the Treatment of Men with Lower Urinary Tract Symptoms Secondary to BPH. Actas Urol Esp [online]. 2007, vol.31, n.2, pp.86-91. ISSN 0210-4806.

Use of antimuscarinic agents in male patients with lower urinary tract symptoms (LUTS) secondaryto benign prostatic hyperplasia (BPH) and with symptoms of overactive bladder (OAB) has become increasingly relevant over the last few years. Prescription of these drugs is in conflict with a long-established concept learnt in Medical School: antimuscarinics are contraindicated in patients with BPH. Several factors, however, have placed this issue under constant review. The description of OAB syndrome and the scientific research carried out over recent years have provided epidemiological and pathophysiological data worthwhile reviewing, most importantly in order to understand why a review of such a solidly established concept has been raised. This paper reviews the prevalence of OAB in men with BPH, the role of urodynamics to evaluate men with OAB and the existing evidence on the effectantimuscarinics have in terms of efficacy and safety on male patients with detrusor obstruction and overactivity.

Palavras-chave : Male overactive bladder; Antimuscarinics.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons